ENTITY

SIGA Technologies (SIGA US)

29
Analysis
Health CareUnited States
SIGA Technologies, Inc. operates as a commercial-stage pharmaceutical company. The Company offers oral formulation of an antiviral drug for the treatment of human smallpox disease caused by variola virus.
more
14 Nov 2025 00:00Issuer-paid

SIGA Technologies — Fundamentals intact amid several moving parts

Q325 was a quieter quarter for SIGA following strong Q2 sales, although this was not unexpected given its contract-driven model and inherent...

Share
12 Aug 2025 22:00Issuer-paid

SIGA Technologies — A solid quarter for topline growth

Q225 was a strong quarter for SIGA, supported by material topline traction, with deliveries of $79m of oral and IV TPOXX to the US strategic...

Share
13 May 2025 12:00Issuer-paid

SIGA Technologies — Another strong period for the order book

Q125 marked another active period for SIGA’s order book, with BARDA exercising the final $26m intravenous (IV) TPOXX option in March, expected to...

Share
10 Apr 2025 16:00Issuer-paid

SIGA Technologies — Dividends bring cheer amid market uncertainty

SIGA Technologies has declared a special dividend of $0.6 per share, marking a fourth straight year of dividend declarations. The outlay is at a...

Share
19 Mar 2025 19:00Issuer-paid

SIGA Technologies — Entering a crucial period for business outlook

SIGA Technologies reported another year of top-line growth in FY24, with performance weighted to Q4, driven by material TPOXX deliveries to both...

Share
x